PRA Health Sciences is part of the healthcare sector and is in the medical diagnostics and research industry. The company CEO is Colin Shannon. PRA Health Sciences Inc is a United State based full-service global contract research organization. It provides a broad range of product development services for pharmaceutical and biotechnology companies around the world.
Previous Intraday Trading Performance:
The PRAH stock showed a previous change of 5.51% with an open at 88.02 and a close of 91.86. It reached an intraday high of 91.97 and a low of 87.81.
SeekingAlpha: What’s Eating PRA Health Sciences’ Stock? Could It Be The Competition?
Liquidity:
The stock has a market cap of $6.0b with 65.7m shares outstanding, of which the float is 65.6m shares. Trading volume reached 987,979 shares compared to its average volume of 683,195 shares. Based on the current average volume and close price, the trading liquidity is good.
Historical Trading Performance:
Over the last five trading days, PRA Health Sciences shares returned 4.95% and in the past 30 trading days it returned -4.24%. Over three months, it changed -15.39%. In one year it has changed 7.30% and within that year its 52-week high was 121.98 and its 52-week low was 82.12. PRAH stock is 11.86% above its 52 Week Low.
Our calculations show a 200 day moving average of 101.84 and a 50 day moving average of 96.39. Currently PRAH stock is trading -9.80% below its 200 day moving average and may not be a good opportunity to buy as it may continue to trend down.
SeekingAlpha: PRA Health Sciences, Inc. (PRAH) CEO Colin Shannon on Q1 2019 Results – Earnings Call Transcript
Earnings:
The last annual fiscal EPS for the company was reported at 2.33 that ended on 31st of December 2018, which according to the previous close, that is a PE of 39.42. Based on 6 analyst estimates, the consensus EPS for the next quarter is 0.95. The TTM EPS is 3.94, which comes to a TTM PE of 23.31.
Below was the last reported quarterly diluted earnings per share:
| 1st | Qtr of 2019 | (Reported on 05/01/2019): | 0.66 |
|---|---|---|---|
| 4th | Qtr of 2018 | (Reported on 02/27/2019): | 1.07 |
| 3rd | Qtr of 2018 | (Reported on 10/31/2018): | 0.02 |
| 2nd | Qtr of 2018 | (Reported on 08/01/2018): | 0.64 |
| 1st | Qtr of 2018 | (Reported on 04/25/2018): | 0.59 |
Base on our calculations, the intrinsic value per share is 105.40, which means it is possibly undervalued and has a margin of safety of 12.85%.
Indicators to Watch:
The current calculated beta is 1.08.
SeekingAlpha: PRA Health Sciences, Inc. (PRAH) CEO Colin Shannon on Q1 2019 Results – Earnings Call Transcript
Fundamental Indicators:
Based on last reported financials, the company’s return on equity is 16.20%, return on assets is 4.95%, profit margin is 5.56%, price-to-sales is 1.98 and price-to-book is 5.16.
Company Scores:
All scores are out of six:
0 :Valuation Score
4 :Past Performance Score
3 :Financial Strength Score
4 :Future Growth Score
0 :Dividend Score
2 :Overall Score
